Net Income

February saw 3.8 billion robocalls, a yearly drop. But a rise in daily call rates and massive scam campaigns show the fight is far from over.

WEBTOON elevates Yongsoo Kim to President, a strategic move to tackle slowing growth and accelerate innovation after a challenging post-IPO period.

As AI adoption outpaces oversight, Check Point’s new advisory service aims to help enterprises manage risk and navigate complex new regulations like the EU AI Act.

A new partnership is pioneering a data-driven family engagement platform, setting a new standard for pediatric health and digital transformation.

At MWC26, iFLYTEK launched ambitious AI translation glasses, but faces stiff competition from Google and Alibaba, along with lingering privacy questions.

BioRestorative Therapies is leveraging its clinical-grade regenerative medicine to disrupt the aesthetics industry. Can science beat marketing?

CIBC's move to pay back $1B in debentures five years ahead of schedule highlights its strong liquidity and proactive capital management strategy.

A new survey reveals over half of Americans delay healthcare, creating a 'health debt' crisis fueled by cost fears and scheduling conflicts for younger generations.

A new partnership between Always and The Fibroid Foundation aims to break the silence on heavy periods and fibroids, combining product innovation with advocacy.

With book value soaring, Stack Capital offers a rare public window into the massive valuations of private titans like SpaceX and the AI infrastructure boom.

AI firm YXT.com lands on a top innovation list with tech giants, but can its cutting-edge training solutions navigate a complex market and redefine work?

Taiwanese biotech GNTbm's oral drug GNTbm-38, which turns 'cold' tumors 'hot', will begin Phase 1 trials for advanced and refractory cancers.

Starton Therapeutics files patents to combine its continuous low-dose therapy, STAR-LLD, with CAR-T, aiming to enhance cancer-killing power and durability.

Iconic Australian bootmaker R.M.Williams expands its partnership with Bamboo Rose, leveraging AI-powered planning to modernize its global operations.

With FDA Breakthrough status for its MASH drug, a new CEO, and a fortified balance sheet, Altimmune is poised to take on serious liver disease and addiction.

With no approved treatments for the deadly pregnancy complication preeclampsia, one company's novel drug is now advancing to a crucial new clinical trial.

The biotech firm accelerates a key trial but faces a partner loss, widening losses, and a CEO search, putting its promising siRNA pipeline at a crossroads.

With a total of $160M in Series B funding, Atavistik Bio is advancing its selective allosteric inhibitors for rare diseases HHT and MPNs.

With a melanoma drug on track for 2027 and a deep pipeline, Immatics' 2025 net loss is part of a larger strategy to dominate PRAME cancer therapy.

Ituran announces a $30M dividend after a record year, leveraging a unique Israeli tax law to boost shareholder returns and signaling deep confidence.